MHRA approves new dose for treating alopecia areata


Share post:

The new medication is said to reduce inflammation

The Medicines and Healthcare products Regulatory Agency (MHRA) has authorised a new drug today (1 November) to treat severe alopecia areata.

Litfulo is the new hard capsule medicine with a recommended dosage of just 50 mg per day.

It contains an active ingredient, ritlecitinib, an enzyme inhibitor treatment for patients over 12 years.

Ritlecitinib works by reducing the activity of enzymes in the body called JAK3 and TEC kinases that cause hair follicle inflammation.

This reduction in inflammation leads to hair regrowth in patients with alopecia areata.

Alopecia areata is an autoimmune disease, where the body’s own immune system attacks hair follicles leading to hair loss on the scalp and other parts of the body.

The most common side effects of the medicine include headache, diarrhoea, dizziness, acne, rash, tuberculosis (TB), and shingles.

Pharmacy Business has contacted MHRA for further information.


Please enter your comment!
Please enter your name here

Current Issue October 2023

Related articles

Over 81% of GP practices in England now provide patients’ health records online, says NHSE

In October alone, more than nine million people viewed their health records through the NHS App Thanks to...

Former Lloyds Pharmacy in Cumnock reopens as Rowlands Store

The new branch will be run by Pharmacy manager Meghan Mcewan and a team of colleagues from the...

Boots closing two stores in North Wales in early 2024

A petition has been launched to save a Boots pharmacy in Bournville from closure The pharmacy chain has already...

Living wage hike to incur up to £195 million in costs for pharmacy sector: CPE

Pharmacies have experienced a 30 per cent real terms funding reduction since 2015. The proposed increase in the national...